A capillary zone electrophoresis method to investigate the oligomerization of the human Islet Amyloid Polypeptide involved in Type 2 Diabetes

被引:7
|
作者
Berardet, Corentin [1 ,2 ]
Kaffy, Julia [2 ]
Ongeri, Sandrine [2 ]
Taverna, Myriam [1 ]
机构
[1] Univ Paris Saclay, Univ Paris Sud, CNRS, PNAS,Inst Galien Paris Sud,UMR 8612, 5 Rue Jean Baptiste Clement, F-92290 Chatenay Malabry, France
[2] Univ Paris Saclay, Univ Paris Sud, CNRS, Fluorinated Molecules & Med Chem,BioCIS,UMR 8076, 5 Rue Jean Baptiste Clement, F-92290 Chatenay Malabry, France
关键词
Type; 2; diabetes; Islet amyloid polypeptide; Capillary zone electrophoresis; CE-MS; Amyloid oligomerization; Inhibitor; THIOFLAVIN-T-BINDING; BASIC-PROTEINS; AMYLIN; PH; AGGREGATION; RESVERATROL; INHIBITOR; MECHANISM; PEPTIDES; LAYER;
D O I
10.1016/j.chroma.2018.10.006
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Type 2 diabetes is characterized by the aggregation of human Islet Amyloid Polypeptide (hIAPP) from monomer to large and insoluble fibrils. According to several recent studies, small soluble oligomers are now considered as potential toxic species. No monitoring tool has been to date reported to mimic in vitro the oligomerization process of hIAPP over time, although this would allow selecting candidate compounds that slow down or stop this pathological process. Considering the poor stability of those species and the necessity to monitor in real time, a compatible with the monitoring of hIAPP oligomerization CE method coupled to UV detection was developed. Three groups of hIAPP oligomers/monomers formed during this process could be separated. A polybrene coating was used to avoid adsorption of hIAPP onto capillary walls. Peaks identification was performed using a combination of CE-MS, filtrations and SDS-PAGE. They revealed that one peak is composed of monomer with a very small amount of dimer and trimer, whereas the two others are composed of bigger species higher than 100 kDa. We demonstrated that this real time oligomerization process started from the very initial step, with hIAPP principally as a monomer, until the formation of very big oligomers. This method was shown to be repeatable with RSDs on electrophoretic mobilities and relative peak areas less than 1.6 and 5.8% respectively for the monomer peak. Its application to study the anti-aggregation properties of resveratrol showed that this compound saved more than 30% of the monomeric hIAPP form whereas it almost disappeared without. The method opens new perspectives for the screening of potential drugs for type 2 diabetes. (C) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:83 / 90
页数:8
相关论文
共 50 条
  • [1] Islet amyloid polypeptide and type 2 diabetes
    Marzban, L
    Park, K
    Verchere, CB
    EXPERIMENTAL GERONTOLOGY, 2003, 38 (04) : 347 - 351
  • [2] Oligomerization of islet amyloid polypeptide precedes the development of diabetes
    He, Caren L.
    Sui, Y.
    Zhu, X.
    Liu, L. Z.
    Gu, X. M.
    Zhao, H. L.
    Lai, F. M. M.
    Tong, P. C. Y.
    Chan, J. C. N.
    DIABETES, 2007, 56 : A683 - A683
  • [3] ISLET AMYLOID POLYPEPTIDE - THE CAUSE OF TYPE-2 DIABETES
    BRETHERTONWATT, D
    BLOOM, SR
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1991, 2 (06): : 203 - 206
  • [4] Human islet amyloid polypeptide: A therapeutic target for the management of type 2 diabetes mellitus
    Roham, Pratiksha H.
    Save, Shreyada N.
    Sharma, Shilpy
    JOURNAL OF PHARMACEUTICAL ANALYSIS, 2022, 12 (04) : 556 - 569
  • [5] Copper Coordination Features of Human Islet Amyloid Polypeptide: The Type 2 Diabetes Peptide
    Sanchez-Lopez, Carolina
    Cortes-Mejia, Rodrigo
    Miotto, Marco C.
    Binolfi, Andres
    Fernandez, Claudio O.
    del Campo, Jorge M.
    Quintanar, Liliana
    INORGANIC CHEMISTRY, 2016, 55 (20) : 10727 - 10740
  • [6] ISLET AMYLOID POLYPEPTIDE - HEN OR EGG IN TYPE-2 DIABETES PATHOGENESIS
    BETSHOLTZ, C
    CHRISTMANSON, L
    GEBREMEDHIN, S
    WESTERMARK, P
    ACTA ONCOLOGICA, 1993, 32 (02) : 149 - 154
  • [7] Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes
    Matveyenko, Aleksey V.
    Butler, Peter C.
    ILAR JOURNAL, 2006, 47 (03) : 225 - 233
  • [8] Inhibitors of islet amyloid polypeptide fibrillogenesis, and the treatment of type-2 diabetes
    Scrocchi, LA
    Chen, Y
    Wang, F
    Han, K
    Ha, K
    Wu, L
    Fraser, PE
    LETTERS IN PEPTIDE SCIENCE, 2003, 10 (5-6): : 545 - 551
  • [9] Inhibitors of islet amyloid polypeptide fibrillogenesis, and the treatment of type-2 diabetes
    Louise A. Scrocchi
    Yan Chen
    Feng Wang
    Kyung Han
    Katherine Ha
    Ling Wu
    Paul E. Fraser
    Letters in Peptide Science, 2003, 10 : 545 - 551
  • [10] Studies of variability in the islet amyloid polypeptide gene in relation to Type 2 diabetes
    Pildal, J
    Lajer, M
    Hansen, SK
    Almind, K
    Ambye, L
    Borch-Johnsen, K
    Carstensen, B
    Hansen, T
    Pedersen, O
    DIABETIC MEDICINE, 2003, 20 (06) : 491 - 494